Lees A J, Stern G M
J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):1020-3. doi: 10.1136/jnnp.44.11.1020.
The progress of 50 previously untreated patients with idiopathic Parkinson's disease taking maximum tolerated doses of bromocriptine is compared with patients who had taken levodopa. Twenty-eight of the bromocriptine treated patients showed sustained benefit for at least one year and in five this persisted longer than five years. Fewer of the late complications of levodopa therapy occurred in those taking bromocriptine; drug-induced dyskinesia was seen in only one patient and oscillations in performance were not observed. There was a tendency for deterioration to develop after two years treatment when patients then failed to respond well to levodopa. It was not possible to extend the period of effective control of disabilities by first giving bromocriptine.
将50例之前未接受过治疗、服用最大耐受剂量溴隐亭的特发性帕金森病患者的病情进展，与服用左旋多巴的患者进行了比较。28例接受溴隐亭治疗的患者显示出至少持续一年的疗效，其中5例的疗效持续超过5年。服用溴隐亭的患者出现左旋多巴治疗晚期并发症的情况较少；仅1例患者出现药物性运动障碍，未观察到疗效波动。接受两年治疗后，当患者对左旋多巴反应不佳时，病情有恶化的趋势。先给予溴隐亭并不能延长有效控制残疾的时间。
